Alterity Therapeutics Stock Performance
| ATHE Stock | USD 3.72 0.27 6.77% |
Alterity Therapeutics holds a performance score of 20 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.45, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Alterity Therapeutics are expected to decrease at a much lower rate. During the bear market, Alterity Therapeutics is likely to outperform the market. Use Alterity Therapeutics expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on Alterity Therapeutics.
Risk-Adjusted Performance
20 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Alterity Therapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak technical indicators, Alterity Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (6.77) | Five Day Return 11.04 | Year To Date Return (0.27) | Ten Year Return (96.00) | All Time Return (99.45) |
Last Split Factor 1:10 | Last Split Date 2023-01-09 |
1 | 5 Beginner Breathing Exercises to Help Banish Stress | 10/24/2024 |
2 | Prana Life Sciences Unveils Rebranding and Renewed Focus on AI Capabilities | 11/12/2024 |
3 | Alterity Therapeutics announces change in company secretary | 11/19/2024 |
4 | Bank of America Co. Shares Bought by Prana Capital Management LP | 12/04/2024 |
5 | Maxim Group Initiates Coverage of Alterity Therapeutics Limited - Depositary Receipt with Buy Recommendation - MSN | 12/12/2024 |
| Begin Period Cash Flow | 15.8 M | |
| Free Cash Flow | -12.6 M |
Alterity |
Alterity Therapeutics Relative Risk vs. Return Landscape
If you would invest 131.00 in Alterity Therapeutics on October 9, 2024 and sell it today you would earn a total of 241.00 from holding Alterity Therapeutics or generate 183.97% return on investment over 90 days. Alterity Therapeutics is currently generating 1.9406% in daily expected returns and assumes 7.3828% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Alterity, and 62% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Alterity Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alterity Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Alterity Therapeutics, and traders can use it to determine the average amount a Alterity Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2629
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ATHE | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.38 actual daily | 65 65% of assets are less volatile |
Expected Return
| 1.94 actual daily | 38 62% of assets have higher returns |
Risk-Adjusted Return
| 0.26 actual daily | 20 80% of assets perform better |
Based on monthly moving average Alterity Therapeutics is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Alterity Therapeutics by adding it to a well-diversified portfolio.
Alterity Therapeutics Fundamentals Growth
Alterity Stock prices reflect investors' perceptions of the future prospects and financial health of Alterity Therapeutics, and Alterity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Alterity Stock performance.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 24.77 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 4.36 X | ||||
| Price To Sales | 8.68 X | ||||
| Revenue | 4.02 M | ||||
| Gross Profit | 3.63 M | ||||
| EBITDA | (19.57 M) | ||||
| Net Income | (19.12 M) | ||||
| Cash And Equivalents | 34.81 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 159.04 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.07 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (12.61 M) | ||||
| Earnings Per Share | (6.99) X | ||||
| Market Capitalization | 34.88 M | ||||
| Total Asset | 19.22 M | ||||
| Retained Earnings | (214.16 M) | ||||
| Working Capital | 13.66 M | ||||
| Current Asset | 14.26 M | ||||
| Current Liabilities | 1.73 M | ||||
About Alterity Therapeutics Performance
By analyzing Alterity Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Alterity Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Alterity Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Alterity Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.90) | (0.94) | |
| Return On Capital Employed | (1.63) | (1.55) | |
| Return On Assets | (1.14) | (1.20) | |
| Return On Equity | (1.59) | (1.51) |
Things to note about Alterity Therapeutics performance evaluation
Checking the ongoing alerts about Alterity Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Alterity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Alterity Therapeutics is way too risky over 90 days horizon | |
| Alterity Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.63 M. | |
| Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Alterity Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Maxim Group Initiates Coverage of Alterity Therapeutics Limited - Depositary Receipt with Buy Recommendation - MSN |
- Analyzing Alterity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Alterity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Alterity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Alterity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Alterity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Alterity Therapeutics' stock. These opinions can provide insight into Alterity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |